Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001104659-24-019725
Filing Date
2024-02-13
Accepted
2024-02-13 14:24:52
Documents
1
Group Members
FORESITE CAPITAL FUND V, L.P.FORESITE CAPITAL MANAGEMENT IV, LLCFORESITE CAPITAL MANAGEMENT V, LLCJAMES TANANBAUM

Document Format Files

Seq Description Document Type Size
1 SC 13G/A tm245717d2_sc13ga.htm SC 13G/A 90260
  Complete submission text file 0001104659-24-019725.txt   92023
Mailing Address 701 LEE ROAD SUITE 103 WAYNE PA 19087
Business Address 701 LEE ROAD SUITE 103 WAYNE PA 19087 484-324-7933
Aclaris Therapeutics, Inc. (Subject) CIK: 0001557746 (see all company filings)

EIN.: 460571712 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A | Act: 34 | File No.: 005-89137 | Film No.: 24624726
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 600 MONTGOMERY STREET, SUITE 4500 SAN FRANCISCO CA 94111
Business Address 600 MONTGOMERY STREET, SUITE 4500 SAN FRANCISCO CA 94111 415-877-4887
Foresite Capital Fund IV, L.P. (Filed by) CIK: 0001704131 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A